CompoAtlas

RADIS NOIR ARTICHAUT FENOUIL

Food supplement declared in France, decision dated 26 August 2026

RADIS NOIR ARTICHAUT FENOUIL (Kersiens PhytoNutrition) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Cynara scolymus 100 mg per day, Foeniculum vulgare 50 mg per day, Raphanus raphanistrum 8.3 ml per day, Foeniculum vulgare 2 mg per day. 1 rule of use applies to its ingredients (limits and warnings).

Brand
Kersiens PhytoNutrition
Food business operator placing the product on the market
MAYOLY CONSUMER HEALTHCARE
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Ampoule
Daily dose
1 ampoule
Directions for use
1 ampoule par jour, à diluer dans un verre d'eau
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, History of breast cancer, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Taking thyroid medication, Prolonged use, Children (under 6), Children (under 10)
Objectives stated by the manufacturer (these are not authorised claims)
Detox / Drainage, Digestion

Declaration 371893, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Cynara scolymus L.FeuilleExtrait fluide aqueux100 mg
Foeniculum vulgare Mill.FruitExtrait sec aqueux50 mg
Raphanus raphanistrum subsp. sativus (L.) DominRacinePression à froid8.3 ml
Foeniculum vulgare Mill.Essence (fruit)Distillation2 mg

Other ingredients

Eau purifiée

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Réservé à l'adulte. Déconseillé aux femmes enceintes ou allaitantes. Déconseillé en cas d'hypothyroïdie, ou de traitement de la thyroïde (consulter préalablement un professionnel de santé), en cas d'obstuction billiaire ou d'autres troubles liés à la fonction billiaire, en cas d'allergie croisée connue en particulier aux plantes de la famille des astréacées et des apiacées, au pollen d'amoisie, ou a l'anéthol ou en cas de prise concomitante ede médicament du système nerveux central. Déconseillé chez les femmes ayant des antécédents de cancer du sein. Ne pas dépasser 14 jours de prise.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Foeniculum vulgare Mill.
    Read the warning, when it applies and the studies cited

    BITTER FENNEL- FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Condition of application: Essential oil and Tincture.

    Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).

    Sources cited by Health Canada (1)
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Health Canada monograph dated 29 November 2024

    SWEET FENNEL -FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Health Canada monograph dated 29 November 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : Kersiens PhytoNutrition

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “RADIS NOIR ARTICHAUT FENOUIL (Kersiens PhytoNutrition): composition and regulation”, https://compoatlas.com/en/supplements/products/371893-radis-noir-artichaut-fenouil, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line